Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: Multicenter trial

European Journal of Neurology

Volumn 11, Issue 11, 2004, Pages 734-741

  Pirttilä, Tuula ^a,d   Wilcock, G ^b   Truyen, L ^c   Damaraju, C V ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d NONE   (Finland)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Clinical trials; Cognitive function; Efficacy; Galantamine; Safety

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELDERLY CARE; FALLING; FEMALE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; WORLD HEALTH ORGANIZATION;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; LONG-TERM CARE; MALE;

EID: 9344231915     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.00885.x     Document Type: Article

References (24)

1. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C (1985). The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann NY Acad Sci 444:332-358.
2. Davies P, Maloney AJ (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
3. Feldman H, Sauter A, Donald A et al, (2001). The Disability Assessment for Dementia Scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 15:89-95.
4. Folstein MF, Folstein SE, McHugh PR (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
5. Gelinas I, Gauthier L, McIntyre M, Gauthier S (1999). Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 53:471-481.
6. Imbimbo BP, Verdelli G, Martelli P, Marchesini D (1999). Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group. Dementia and Geriatric Cognitive Disorders 10:139-147.
7. Janssen Research Foundation (1999a). Data on file, Study Report No. GAL-INT-3, Titusville, NJ.
8. Janssen Research Foundation (1999b). Data on file, Study Report No. GAL-INT-7, Titusville, NJ.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
10. Mohs RC, Davis KL, Levy MI (1981). Partial reversal of anticholinergic amnesia by choline chloride. Life Sci 29:1317-1323.
11. Murray CL, Fibiger HC (1985). Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine. Neuroscience 14:1025-1032.
12. Olin J, Schneider L (2002). Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database of Systemic Reviews CD001747.
13. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 2:1457-1459.
14. Raskind MA, Peskind ER, Wessel T, Yuan W (2000). Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261-2268.
15. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D (2001). Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of Neurology, Neurosurgery, and Psychiatry 71:589-595.
16. Rogers SL, Friedhoff LT (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8:67-75.
17. Rosen WG, Mohs RC, Davis KL (1984). A new rating scale for Alzheimer's disease. Am J Psychiatry 141:1356-1364.
18. Saper CB, German DC, White CL III (1985). Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology 35:1089-1095.
19. Stern RG, Mohs RC, Davidson M et al (1994). A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151:390-396.
20. Sweeney JE, Hohmann CF, Moran TH, Coyle JT (1988). A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 31:141-147.
21. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54:2269-2276.
22. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122-126.
23. Wilcock GK, Lilienfeld S, Gaens E (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 321:1445-1449.
24. Yankner BA, Mesulam MM (1991). Seminars in medicine of the Beth Israel Hospital, Boston. β-amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 325:1849-1857.